Management of Lamotrigine-Induced Dizziness
If a patient experiences dizziness from lamotrigine, first assess whether this is acute toxicity requiring dose reduction or a transient side effect during titration that may resolve with continued therapy. 1
Immediate Assessment
Check lamotrigine serum level immediately if available, as dizziness is a common manifestation of toxicity, particularly when levels exceed therapeutic range. 2
- Dizziness occurs significantly more frequently with lamotrigine than placebo but is typically dose-related 3, 4
- In patients presenting with dizziness, ataxia, or diplopia, lamotrigine toxicity is frequently misdiagnosed as posterior circulation stroke, leading to unnecessary stroke evaluations 2
- Critical pitfall: Emergency departments often initiate stroke workups in older patients (mean age 62 years) with lamotrigine-induced dizziness, but lamotrigine levels are rarely available rapidly enough to prevent this costly evaluation 2
Management Strategy Based on Clinical Context
During Dose Titration or Recent Increase
- Dizziness during titration is common and often transient 4
- Consider slowing the titration rate rather than discontinuing therapy
- The FDA label notes that dizziness is among the CNS adverse effects that should prompt caution about driving and operating machinery 1
Established Therapy with New-Onset Dizziness
Reduce the lamotrigine dose immediately if toxicity is suspected, particularly if accompanied by ataxia, diplopia, or nausea. 2, 3
- Mean toxic doses in case series were 621 mg/day (range 300-900 mg) 2
- Dizziness risk ratio versus placebo is 2.00 (99% CI 1.52-2.64), indicating significantly increased risk 3
- Ataxia co-occurs frequently (RR 3.34,99% CI 2.01-5.55) 3
Consider Formulation Switch
Convert from immediate-release to extended-release lamotrigine if peak-related dizziness persists despite dose optimization. 5
- Extended-release formulation reduces peak-to-trough fluctuations that cause dizziness and other CNS side effects 5
- In one study, 47% of patients converting to extended-release experienced improved seizure control, with 7 patients reporting improvement in adverse effects including dizziness 5
- Conversion can be done at the same total daily dose or with slight adjustments 5
Drug Interactions to Evaluate
Review concomitant medications that may increase lamotrigine levels:
- Valproate significantly increases lamotrigine levels and toxicity risk 1
- Estrogen-containing contraceptives decrease lamotrigine levels; stopping them (including pill-free weeks) can cause sudden level increases and toxicity 1
- Enzyme-inducing antiepileptics (carbamazepine, phenytoin, phenobarbital) decrease lamotrigine levels 1
Special Populations
Older Adults
- Older patients are at higher risk for dizziness and balance problems with lamotrigine 2, 6
- Lamotrigine may cause less disequilibrium than carbamazepine in older adults on monotherapy 6
- Start at lower doses in elderly patients, particularly those with hepatic impairment 1
Hepatic Impairment
- Reduce initial, escalation, and maintenance doses by approximately 25% in moderate hepatic impairment and 50% in severe impairment with ascites 1
Monitoring Recommendations
- Do not advise driving or operating complex machinery until dizziness resolves 1
- Monitor for associated symptoms suggesting serious toxicity: ataxia, diplopia, nausea, decreased consciousness 1, 3
- If dizziness persists despite dose reduction, consider alternative antiepileptic therapy
- The FDA label specifically warns that lamotrigine "may cause dizziness, somnolence, and other symptoms and signs of central nervous system depression" 1
When to Discontinue
Hospitalize and provide supportive care if overdose or severe toxicity is suspected with decreased level of consciousness, seizures, or cardiac conduction abnormalities. 1